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ABSTRACT
Hepatocellular carcinoma is relatively infrequent 
in childhood. Hepatocellu lar carcinom a in 
younger than age 15 is also associated with 
hepatitis B virus as seen in adult population.
Here two HCC cases due to hepatitis B have 
been presented.
K e y  W o r d s :  Hepatocellu lar Carcinoma
Hepatitis B, Childhood
IN T R O D U C T IO N
Primary liver tumours form 0.5-2 % of all 
childhood tumours (1). About 57% of these are 
malignant and hepatoblastom a and 
hepatocellular carcinoma (HCC) are the most 
frequent. Though cases as young as 21 months 
old have been reported, HCC is generally 
regarded as an older child's disease (2,3). 
Hepatitis B infection and more rarely elongated 
prolonged total parenteral digestion, anabolic 
steroids, tyrosinemia biliary atresy alpha -1- 
antitrypsine deficiency and glucogene storage 
diseases are among the risk factors of HCC 
formation (1).
CASE 1
A 13-year-old male patient who presented at the 
pediatrics clinic with complaints such as pain in 
the epigastrium  and right upper quadrant. 
Physical exam ination revealed the liver to 
overpass the thoracal rib-cage line by 2 cms at 
midclavicular line. The liver was palpated as a 
hard tissue with blunt angles and was painful. 
Laboratory tests revealed 8.2 grams of 
haemoglobin, leukocytes af 8.540 and platelets 
as 213 000. The aminotransferases (SGOT and 
SGPT), gamma-glutamyl transpeptidase (GGT) 
and alkaline phosphatase levels were elevated 
up to three times the normal. Serum copper, 
seruloplasm in, a lpha-1-antitrypsine and 
immunoglobulin levels were found to be normal. 
Anti-Hepatitis C virus (HCV), cytomegalovirus 
(CMV), ebstein-barr virus (EBV), immunoglobulin 
G antibodies were negative. Hepatitis B markers 
were also negative except for positive hepatitis-B 
carrierness. Ultrasound investigation revealed 
mass lesions on both liver lobes with irregular 
contours, various sizes and mixed echogenities. 
The serum alpha feto protein (AFP) levels were 
100 tim es over normal. Computarized 
tomography (CT) scan revealed hypodensed 
solid masses suggesting necrosis which were 
hardly differentiated from normal tissue. (Fig. 1)
(Accepted 3 March, 2000) Marmara Medical Journal 2000;13(2):94-97
94
Hepatocellular childhood carcinoma
F ig . 1 .:  Computarized tomography scan noted multiple hypodensed solid masses in the liver.
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Fig.2,3: Microscopic appearance of the tumor shows trabecular type HCC.
Histopathological investigation of the liver biopsy 
ended up with trabecular type HCC diagnosis. 
(Fig. 2-3) Family scanning of the patient revealed 
that his siblings also had hepatitis B surface 
antigen (HbsAg) positiveness.
CASE 2
A 10-year-old male patient who presented at the 
pediatrics clinic with complaints of pain in the 
epigastrium and right upper quadrant. The liver 
exceeded the thoracal ribcage line by 4 cms at
the physical examination. The liver was hard, 
with blunt angles and nodular surface and 
painful. The spleen was not palpable. Laboratory 
tests revealed haemoglobin 10.5 g/dl, 
haematocrit 32.6%, leukocyte count as 12.300 
and platelets 227.000. SGOT, SGPT, GGT, 
alkaline phosphatase levels were 4 times over 
the normal limits Serum copper, seruloplasmine, 
alpha-1-antitrypsine and immunoglobulin levels 
were normal. Anti-HCV, CMV, EBV 
immunoglobulin G antibodies were negative. 
Among the Hepatitis B virus (HBV) markers, 
HbsAg, core antibody total and hepatitis B e
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antibody (anti-Hbe) were positive but HBV 
deoxyribonucleic acid (DNA) was negative. 
Ultrasound examination revealed mass lesions 
on both lobes, with various sizes, irregular 
contours and mixed echogenities. Serum AFP 
level was 200 times over normal limits. A CT 
scan revealed hypodensed solid masses not 
clearly differentiated from normal paranchyma 
which suggested necrosis. Pathological 
examination of the liver biopsy revealed 
trabecular-type HCC diagnosis. In family history 
an uncle from the mother's side had died from 
liver cancer and all family members were HbsAg 
positive.
Neither of the two cases were operable as the 
masses were widespread over both liver lobes. 
Cysplatin and adriablastin medications were 
given after consulting with the pediatric oncology 
department. Both patients died due to bleeding 
after worsening of the liver functions.
D IS C U S S IO N
Hepatocellular carcinoma due to hepatitis B 
generally develops in about 20 years. But this 
duration is much shorter in childhood (4). 
Children developing HCC due to hepatitis B face 
the infection primarily through maternal passage. 
Perinatal transmission is particularly important as 
it causes a high level of hepatitis B carrierness. 
About 95% of the newborn cannot get rid of the 
virus and become chronic carriers (5). 
Epidemiological and molecular biology studies 
and animal tests showed the importance of 
hepatitis B infection on the development of HCC
(6,7). Studies in Taiwan and Senegal showed 71- 
86% of the HCC patients had been HBsAg 
positive. In the series of Chang et al. (9) this ratio 
was 71.2%. Both of our patients were HBsAg 
positive.Hepatitis B e antigen (HbeAg) is the 
marker showing the production of the HBV in the 
host. Studies revealed that HCC patients with 
negative HBe Ag and positive anti-HBe were not 
at production phase for the virus. The viral DNA 
was integrated into the host DNA (10,11). Again 
the patients in Taiwan and Senegal revealed 
14.3% positive tests for HBeAg and 78.6% 
positive for anti-HBe. (9). One of our patients was 
anti-HBe positive and HBV DNA negative. This 
shows that the patient did not have any viral
production and the DNA of the host was in 
interactivity with viral DNA.
Hepatocellular carcinoma goes with elevated 
Alfa-feto protein levels in 75-92% of the cases
(12,13). Alfa-feto protein level is a sign of the size 
of the tumour, thus it can be important for the 
evaluation of the response to the treatment (14). 
Mortality levels were also increased for those 
patients revealing increased AFP levels (13). In 
regard to the relationship between the increased 
serum AFP levels and mortality rates, we must 
note that both of our cases died. But the 
relatiohship between the AFP levels and the 
treatment response could not be evaluated as 
the patients died in a relatively short period.
Although surgery is the main treatment method, 
the tumour can only be removed in less than 30% 
of the cases due to widespread infiltration of both 
lobes (1, 15, 16). Chemotherapy is the other 
option for those who cannot receive surgery (17). 
Various combinations of new chemotherapy 
regimes and surgery have a tem porarily 
beneficial effect, and the prognosis is still poor 
(17-19). Neither of our patients could be operated 
as the tumour had widely infiltrated both lobes of 
the liver. The patient had been started to receive 
chemotherapy but died due to bleeding caused 
by liver failure.
Hepatocellular carcinoma is one of the rare 
cancers with poor prognosis seen in childhood. 
Intensive vaccination of communities for hepatitis 
B within the perinatal period upto 12 years of age 
is very important in moderate and highly endemic 
regions protection from HCC which can be a late 
complication of hepatitis B infection. Vaccination 
can decrease the incidence of HCC.
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